Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Reports Preliminary 2025 Financial Results and Business Highlights
Summary
Apellis Pharmaceuticals, Inc. announced preliminary U.S. net product revenues of approximately $689 million for the full year 2025. The company reported strong growth in demand for SYFOVRE and continued expansion of EMPAVELI in rare diseases. Apellis ended the year with approximately $466 million in cash and cash equivalents, positioning the company to fund operations to profitability. The company also discussed strategic priorities for 2026, focusing on expanding its geographic atrophy market and advancing SYFOVRE's competitive position.
Profitelligence Alerts
Get alerts for APLS
Be first to know when Apellis Pharmaceuticals Inc. files with the SEC.
Filing Categories
Advertisement
About Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing novel therapeutic compounds to address complement-mediated diseases. The primary focus of Apellis is to pioneer medicines leveraging targeted inhibition of the complement system, a key component of the immune system that plays a crucial role in a variety of diseases. The company's flagship product, targeting diseases such as geographic atrophy and paroxysmal nocturnal hemoglobinuria (PNH), highlights its commitment to addressing unmet medical needs with innovative treatments. Apellis Pharmaceuticals operates in the highly competitive pharmaceutical and biotechnology industry, collaborating with healthcare providers and research institutions to advance clinical treatment options. Headquartered in Waltham, Massachusetts, its contributions to medical science are significant, paving the way for advancements in immunology and therapy development. As a publicly traded entity, Apellis influences the healthcare sector by enhancing treatment paradigms and offering new hope for patients with chronic and debilitating conditions.
Official SEC Documents
Advertisement